Claire is a contentious IP specialist. She works in a variety of sectors including pharmaceuticals, biotechnology, medical devices, chemicals and consumer electronics.

Claire is regularly engaged in patent infringement and revocation actions in the UK High Court and Court of Appeal, including preliminary injunction applications. She also has experience in the Intellectual Property Enterprise Court, has assisted with judicial review on regulatory matters, complex damages actions, applications for interim and summary relief, pre-action and third party disclosure and permission to appeal in a number of courts, including the Supreme Court.

Alongside her UK practice, Claire has embraced the global coordination of patent litigation since qualifying in 2011, including developing strategies involving regulatory/competition law aspects.

Some of Claire’s work highlights include:

• Sandoz, Teva & others v Bayer – acting for Teva in a multi-party dispute concerning the validity of Bayer’s patent protection for the dosing regime of rivaroxaban (Xarelto®) at first instance and in the Court of Appeal; including assisting in multiple preliminary injunction applications at first instance and on appeal.
• Teva v Grunenthal – acting for Teva in a patent infringement and validity action concerning the formulation patent covering Grunenthal’s testosterone undecanoate product, Nebido®.
• Teva v Novartis – acting for Novartis in patent litigation concerning a patent protecting deferasirox (Exjade®) in the UK High Court.
• Regeneron & Teva v Rinat – acting for Teva/Regeneron in patent litigation before the English Patents Court concerning anti-NGF an antibody (fasinumab) being trialled for the treatment of osteoarthritis.
• Eli Lilly v Teva – acting for Teva in patent litigation relating to patents for an anti-CGRP antibody, fremanezumab (Ajovy®) used to treat migraine and cluster headache.
• Novartis v Hospira & others – acting for Novartis in patent litigation relating to zoledronic acid (Aclasta®), including in achieving the seminal Court of Appeal decision on preliminary injunctions that confirms that parties must clear the way to the Court of Appeal or risk being injuncted.
• Orion v Secretary of State for Health and Social Care and Ever Neuro – acting for Ever Neuro in judicial review proceedings concerning an MHRA decision to grant a generic MA for dexmedetomidine hydrochloride.
• Smith & Nephew v Convatec – assisting Smith & Nephew in proceedings against Convatex in relation to gel-forming wound dressings (Durafiber®), including a damages claim under a cross-undertaking.
• Assisting multiple large pharmaceutical companies in global coordination relating to patent rights covering treatments (including small molecules, antibodies, non-biological complex drugs) for a diverse range of disorders, including alignment on regulatory matters and competition aspects.

Claire has a particular interest in the life sciences sector. Her biochemical background lends itself to the technical aspects of intellectual property matters, particularly in the pharmaceutical and biotechnology fields. She regularly works alongside lawyers and patent attorneys in various jurisdictions within Europe, Asia, Australasia and the US to coordinate global litigation strategies.

Claire is actively involved in Bristows’ corporate responsibility efforts and chairs the CR Charities Committee.